Reviva to Participate in the Lytham Partners Fall 2026 Investor ConferenceGlobeNewsWire · Sep 22, 2026
Financial Survey: InMed Pharmaceuticals (NASDAQ:INM) & Reviva Pharmaceuticals (NASDAQ:RVPH)Defense World · Aug 13, 2026
Reviva Reports Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewsWire · Aug 12, 2026Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.39 | -$0.19 | Beat |
| May 14, 2026 | -$0.75 | -$0.46 | Beat |
| Mar 30, 2026 | -$1.08 | $0.72 | Beat |
| Nov 13, 2025 | -$1.89 | -$1.20 | Beat |
| Aug 14, 2025 | -$2.35 | -$2.40 | Miss |
| May 15, 2025 | -$3.94 | -$2.60 | Beat |